

PENGANA AXIOM INTERNATIONAL ETHICAL FUND HEDGED

DESCRIPTION

The Pengana Axiom International Ethical Fund (Hedged) invests in companies that are dynamically growing and changing for the better, more rapidly than generally expected and where the positive changes are not yet reflected in expectations or valuation.

The Global Equity Strategy seeks dynamic growth by concentrating its investments in global developed markets, and may also invest in companies located in emerging markets.

The investment manager is Axiom Investors, a Connecticut-based global equity fund manager formed in 1998 with over US\$19billion in assets under Management.

■ STATISTICAL DATAVOLATILITY⁸ 15.2%

NUMBER OF STOCKS 46

BETA⁹ 0.96

The Class was established in 1 July 2017. From June 2021 Axiom was appointed as the investment manager for the Fund.

E PERFORMANCE TABLE

Pengana Axiom International Ethical Fund (Hedged)¹


		1М	1Y	Since Axiom Appointed June 2021	3Y
Fund: APIR (HHA0002AU)*** 3.0% 29.6% -7.5% -1 Managed by Axiom from June 2021	Fund: APIR (HHA0002AU) ^{2,3} Managed by Axiom from June 2021	3.0%	29.6%	-7.5%	-0.5%

Current Strategy (Partial Simulation)⁵
Axiom Global Equity Strategy

Index (Hedged)⁶
3.9% 20.1% -0.6%

3Y	5Y	Since Fund Inception July 2017 ³	Since Strategy Inception July 2004 ⁴
-0.5%	0.3%	7.2%	7.0%
	1.3%	12.5%	9.8%
2.7%	5.9%	11.6%	8.9%

NET PERFORMANCE FOR PERIODS ENDING 31 Dec 2023¹



TOP HOLDINGS (ALPHABETICALLY)		
Adobe Inc	Information Technology	
Alphabet Inc	Communication Services	
Amazon.com Inc	Consumer Discretionary	
Eli Lilly & Co	Health Care	
Microsoft Corp	Information Technology	
Novo Nordisk A/S	Health Care	
NVIDIA Corp	Information Technology	
ServiceNow Inc	Information Technology	
Taiwan Semiconductor Manufactu	Information Technology	
Visa Inc	Financials	

SECTOR BREAKDOWN		CAPITALISATION BREAKDOWN		REGION BREAKDOWN	
Consumer Discretionary	16.3%	Under 5bn USD	1.1%	North America	72.7%
Consumer Staples	3.4%	In between 5bn - 10bn USD	1.3%	Europe ex-UK	15.5%
Financials	7.9%	In between 10bn - 50bn USD	12.2%	Emerging Markets	4.5%
Health Care	15.8%	In between 50bn - 150bn USD	29.9%	Japan	5.1%
Industrials	7.1%	In between 150bn - 500bn USD	20.8%	Asia Pacific ex-Japan	1%
Information Technology	41%	Above 500bn USD	33.6%	Cash	1.2%
Real Estate	1.4%	Cash	1.2%		
Communication Services	6.1%				
Cash	1.2%				

DECEMBER REPORT

COMMENTARY

- Global equities continued to deliver strong gains in local currency terms during December as inflation eased further and the US economy remained resilient.
- Hedging the Fund's foreign currency exposure contributed to returns during the month as the Australian dollar strengthened relative to other major currencies.
- The Portfolio returned 3.0% in December, while the benchmark returned 3.9%, as value stocks outperformed growth.
- The Portfolio completed a very strong year, delivering 29.6%, while the benchmark returned 20.1%, by identifying early those stocks which saw big shifts in their market size and earnings.

December ended a very strong year for the Fund, delivering an exceptionally strong 29.6% absolute return, some 9.5% ahead of its benchmark. This outperformance was driven by the Fund identifying early those companies aligned with secular growth themes such as artificial intelligence (AI), automation, electrification, and obesity treatments, and which were delivering positive change. Quantum shifts in their potential market size brought rapid earnings acceleration, boosting stock valuations.

Global equity markets made further gains during December as inflation continued to moderate. Furthermore, investor expectations grew that the US Federal Reserve (Fed) might begin to cut interest rates in early 2024. Value stocks outperformed growth by 1.1% during December upon signs that central banks may deliver a soft landing, benefitting companies in a broader range of sectors across the economy. This meant the Fund's returns lagged those of the benchmark.

Inflation continues to slow around the world. In the US, the Core Personal Consumption Expenditure (PCE) Price Index, a metric closely watched by the Fed fell to 3.2% year-on-year in November from 3.5% in October. Expectations that the Fed will begin to reduce interest rates ahead of other major central banks pushed the US dollar 2.1% lower against a basket of its key trading partners' currencies in December. It also fell against the Australian dollar.

Economic growth remains mixed. The US labour market and consumers remain resilient, with November retail sales increasing 5.2%, while they fell a further 1.1% in Europe, where leading indicators are consistent with a contracting economy.

China's manufacturing sector continues to show signs of limited expansion, although the broader China "reopening" continues to disappoint expectations. Consumer spending is sluggish, while the highly leveraged property sector remains a drag on economic growth. Travel and entertainment continue to be rare areas of growth in the region.

The Fund retains its focus on dynamic growth stocks, where positive revisions to earnings per share (EPS) drive outperformance as global economic growth moderates. The Fund continues to overweight information technology, consumer discretionary and health care, while underweighting financials, energy, and materials.

Strong stock performance in consumer staples and communication services sectors and the zero weighting to energy contributed to relative returns. Weak stock performance in the information technology, consumer discretionary and industrials were the main detractors.

US cosmetics brand E.I.f. Beauty contributed significantly to relative returns after announcing another quarter of strong earnings growth which was well above expectations. It also raised its full year earnings guidance. The Fund tracks bi-weekly scanner data which continues to show growth that is trending ahead of market expectations over the near-term.

US-based **Zoetis** is the world's largest producer of animal medicines and vaccinations. It contributed to the Fund's relative returns in December after publishing strong third quarter earnings. These should continue to grow as vet visit data tracked by the Fund and industry surveys have been largely positive. It has resolved most of its supply chain issues and received positive initial feedback from the US launch of its osteoarthritis pain medicine Librela.

Taiwan Semiconductor Manufacturing Company (TSMC) is the world's largest pure-play semiconductor business. It contributed to relative returns when it reported October and November sales ahead of investor expectations. This reflected growing generative Al-driven demand and improving trends in the personal computer and smartphone end-markets.

US-based global software group Adobe detracted from relative returns following a period of strong performance. The company reported fourth quarter earnings ahead of expectations but provided disappointing 2024 guidance. Furthermore, it will no longer go ahead with the US\$20 billion acquisition of unlisted software start-up Figma, which is viewed positively by the Fund as this would have initially diluted earnings. Generative AI opportunities offer more compelling opportunities to drive long-term earnings growth.

US-based pharmaceutical company Eli Lilly underperformed in December. This followed a long period of outperformance as investors consider the long-term impact on earnings of its GLP-1 treatments for diabetes and weight loss. This remains an exciting opportunity given its large potential patient base, proven effectiveness and strong safety record.

US-based business advisory firm FTI Consulting also lagged the broader market as US macroeconomic data continues to look healthy. This means that the company's restructuring business' revenue growth may fail to accelerate as much as investors had been expecting. The Fund has reduced its position in the stock accordingly.

The Fund continued to build up its positions in cloud-based document database provider MongoDB and Japanese semiconductor equipment group Tokyo Electron which were first established in November. The position in US-based logistics real estate investment trust Prologis was increased following dovish commentary by Fed officials which seemed to improve the prospects of rate cuts in 2024.

The Fund reduced its position in US-based online vehicle auctioneer Copart. Its market valuation now more fully reflects the Fund's expectations of its medium-term earnings following its extended period of outperformance. The Fund also trimmed its position in pan-Asian life insurance group AIA Group, as the macroeconomic performance in mainland China continues to be weaker than expected.

✓ FEATURES	
APIR CODE	HHA0002AU
REDEMPTION PRICE	A\$ 2.6949
FEES*	Management Fee: 1.35% p.a
MINIMUM INITIAL INVESTMENT	\$10,000
FUM AT MONTH END	A\$ 43.19m
STRATEGY INCEPTION DATE	1 July 2004
BENCHMARK	MSCI All Country World Total Return in AUD (Hedged)

S FUND MANAGERS



Bradley Amoils Managing Director/Portfolio Manager



Andrew Jacobson
CEO/Chief Investment Officer

- 1. From 4 June 2021 the capital component of the foreign currency exposure for the Fund is hedged back to Australian dollars.
- 2. Axiom was appointed fund manager as of 5 May 2021. June 2021 represents the first full month of Axiom managing the Fund.
- 3. Inception date 1 July 2017. Figures shown are calculated from the continuous performance of both the current and previous strategies. For performance see row labelled Fund: APIR (HHA0002AU) in the table above which is the continuous performance of both the current and previous strategies.
- 4. Axiom Global Equity Strategy inception 1 Jul 2004.
- 5. Prior to 1 June 2021, the Axiom Global Equity Strategy performance (labeled 'Current Strategy (Partial Simulation)' and shown in the shaded area) includes the strategy performance simulated by Pengana from the monthly gross USD returns of the Axiom Global Equity strategy. The Axiom Global Equity Strategy performance does not include the Pengana ethical screen
- 6. Prior to 4 June 2021 hedged performance has been simulated by Pengana for both the Fund and Index. This was done by: 1) using 3 month rolling forwards to hedge movements in the AUD/USD spot rate, and 2) deducting the Pengana International Ethical Fund (Hedged) management fee of 1.35% p.a. from the Fund's performance.
- From 4 June 2021, index performance is from the MSCI All Country World Total Return in AUD (Hedged). Prior to 4 June 2021, index performance is simulated from the MSCI All Country World Total Return in LISD.
- 7. Performance for periods greater than 12 months are annualised. Net performance figures are shown after all fees and expenses, and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.
- 8. Annualised standard deviation since inception.
- 9. Relative to the MSCI All Country World Total Return in AUD (Hedged).
- ${}^\star \text{For further information regarding fees please see the PDS available on our website.}$

PENGANA AXIOM INTERNATIONAL ETHICAL FUND HEDGED

PENGANA CAPITAL LIMITED

ABN 30 103 800 568 AFSL 226566 **CLIENT SERVICE**

T: +61 2 8524 9900 F: +61 2 8524 9901

E: clientservice@pengana.com

PENGANA CAPITAL GROUP

PENGANA.COM

Pengana Capital Limited (ABN 30 103 800 568, AFSL 226566) ("Pengana") is the issuer of units in the Pengana Axiom International Ethical Fund (Hedged) (ARSN 098 586 282) (the "Fund"). A product disclosure statement for the Fund is available and can be obtained from our distribution team or website. A person should obtain a copy of the product disclosure statement and should consider the product disclosure statement carefully before deciding whether to acquire, or to continue to hold, or making any other decision in respect of, the units in the Fund. This report was prepared by Pengana and does not contain any investment recommendation or investment advice. This report has been prepared without taking account of any person's objectives, financial situation or needs. Therefore, before acting on any information contained within this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs. Neither Pengana nor its related entities, directors or officers guarantees the performance of, or the repayment of capital or income invested in, the Fund.